<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01295736</url>
  </required_header>
  <id_info>
    <org_study_id>2010-021135-13</org_study_id>
    <secondary_id>2010_14</secondary_id>
    <nct_id>NCT01295736</nct_id>
  </id_info>
  <brief_title>Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY</brief_title>
  <acronym>SEDUCE</acronym>
  <official_title>Evaluation of the Efficacy of Sildenafil on Time to Healing in Patients With Scleroderma and Ischaemic Digital Ulcers: a Prospective, Longitudinal, Randomized, Comparative, Double-blind, 2-parallel-arm, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Digital ulcers (DUs) are an expression of the microangiopathy in patients with scleroderma
      (SSc). DUs lead to pain and impaired hand use. DUs remain a severe complication for many
      patients and effective therapy remains elusive. In the present study, the investigators
      propose to evaluate the efficacy of Sildenafil in DUs healing in a randomized double blind
      control study in SSc patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, prospective, longitudinal, randomized, comparative, double-blind,
      2-parallel-arm, placebo-controlled study aimed to evaluate the efficacy of sildenafil 20 mg
      TID study on time to healing of DUs in SSc patients with ischaemic DUs.

      Approximately 120 patients aged from 18 years and above will be allocated to receive either
      placebo or sildenafil 20mg TID during 90 days. All potential subjects will present with
      ischaemic digital ulcers complicating scleroderma. An eligible digital ulcer must be beyond
      the proximal interphalangeal joint, on finger surface (included periungual ulcers), of
      ischemic origin according to the physician, and not over subcutaneous calcifications or bone
      relief.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to healing of ischemic digital ulcers (DUs) in patients with scleroderma treated by sildenafil 20 mg TID versus placebo for 90 days</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the time to healing of ischemic DUs (2 mm at entry and &gt; 1 month and &lt;3 months old) in patients with scleroderma treated by sildenafil 20 mg TID versus placebo for 90 days.</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the change in the number of ischaemic DUs between baseline and day 90.</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the proportion of patients with complete healing of all DUs present at baseline at day 90.</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the proportion of patients with complete healing of all DUs (baseline DUs and new DUs) at day 90.</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the proportion of patients who do not develop any new DU after 28 days of treatment with the study drug up to day 90.</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the change between baseline and day 90 in hand function and pain.</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the proportion of patients with complicated DUs (infection, gangrene, amputation, DU requiring IV prostanoids) over the 90 days period of treatment.</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the evolution of the severity of Raynaud's phenomenon between baseline and day 90.</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Systemic Scleroderma</condition>
  <arm_group>
    <arm_group_label>Actif arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sildenafil 20mg TID during 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pills TID during 90 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil</intervention_name>
    <description>Sildenafil 20 mg TID per os during 90 days</description>
    <arm_group_label>Actif arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo pills TID per os during 90 days</description>
    <arm_group_label>Sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with systemic sclerosis (ScS) according to the classification criteria of the
             American College of Rheumatology or of &quot;LeRoy&quot; and &quot;Medsger&quot;.

          -  ScS patient with at least one ongoing ischaemic hand digital ulcer at baseline (see
             below the eligibility conditions of a digital ulcer).

          -  Patient must have provided written informed consent prior to enrolment. Patient agrees
             to come to the follow up visits inside the protocol specified range.

          -  Relative to each DU: DU must be beyond the proximal interphalangeal joint, on finger
             surface, of ischemic origin according to the physician, and not over subcutaneous
             calcifications or bone relief.

        Exclusion Criteria:

          -  PAH requiring PDE5 inhibitors or prostacyclin history of stroke, myocardial infarction
             or life threatening arrhythmia within the last 6 months

          -  severe cardiac failure (NYHA IV) or unstable angina within the last 6 months.

          -  hereditary degenerative retinal disorders non-arteritic anterior ischemic optic
             neuropathy or untreated proliferative diabetic retinopathy

          -  uncontrolled diabetes mellitus

          -  Patient with known severe lung obstructive disease (FEV1&lt;70% on last available
             pulmonary function tests).

          -  severe hepatic impairment

          -  Patient with known impairment of renal function (serum creatinine &gt; 2.5 ULN).

          -  Patient with severe malabsorption or any severe organ failure (e.g., lung, kidney) or
             any life-threatening condition.

          -  Patient who has had surgical sympathectomy performed in the previous 12 months.

          -  Patient with a history of upper extremity deep vein thrombosis or lymphedema within
             the previous 3 months.

          -  Patient participating in a clinical trial or having participated in a clinical trial
             within the previous 3 months.

          -  Patient having received a treatment with sildenafil for digital ulcers or pulmonary
             arterial hypertension within 3 months prior to inclusion.

          -  Patient having received a treatment with parenteral prostanoids (prostaglandin E,
             epoprostenol, treprostinil sodium or other prostacyclin analogs) within 3 months prior
             to inclusion.

          -  Patient having received a treatment with inhaled or oral prostanoids one month prior
             to inclusion.

          -  Patient with previous intolerance or allergy to PDE5 inhibitors or a history of
             multiple clinically significant allergies.

          -  Pregnant or lactating female.

          -  Patient with uncontrolled tachyarrhythmias or bradyarrhythmias, or placement of
             pacemaker or implantable defibrillator within 60 days prior to randomization.

          -  Patient with hemodynamic instability or systolic arterial pressure less than 90 mmHg
             and/or symptomatic orthostatic hypotension.

          -  Patient receiving all forms of prostacyclin or nitrates or nitric oxide donors in any
             form including Nicorandil.

          -  Patient receiving potent inhibitors of CYP3A4 such as ketoconazole, itraconazole,
             ritonavir.

          -  Patient with any condition that prevents compliance with the protocol or adhering to
             therapy.

          -  Patient who has donated blood during the previous month or intends to donate blood or
             blood products during the study or for one month following completion of the study.

          -  Patient under guardianship (including curators) or deprived of liberty.

          -  Patient presenting with an anatomic malformation of penis (such as an angulation,
             sclerosis of erectile tissue or &quot;Lapeyronie's disease&quot;).

          -  Patient presenting with a disease which predisposes to priapism (such as sickle-cell
             disease, myeloma or leukemia).

          -  Patient presenting with at least one digital ulcer meeting the exclusion criteria (see
             below).

          -  Relative to each DU:

          -  Digital ulcer due to conditions other than scleroderma.

          -  Non ischaemic digital ulcer.

          -  Infected digital ulcer requiring systemic antibiotherapy.

          -  Digital ulcer requiring urgent surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric HACHULLA, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital, Nice</name>
      <address>
        <city>Nice</city>
        <state>Alpes-Maritimes</state>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hautepierre Hospital</name>
      <address>
        <city>Strasbourg</city>
        <state>Bas-Rhin</state>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nord Hospital</name>
      <address>
        <city>Marseille</city>
        <state>Bouches du Rhone</state>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <state>Calvados</state>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <state>Côte d'Or</state>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dupuytren / dermatology</name>
      <address>
        <city>Limoges</city>
        <state>Haute Vienne</state>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dupuytren / Médecine Interne</name>
      <address>
        <city>Limoges</city>
        <state>Haute Vienne</state>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean Verdier Hospital</name>
      <address>
        <city>Bondy</city>
        <state>Ile de France</state>
        <zip>93130</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Pitié - Salpétriêre Hospital</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cochin Hospital / Médecine Interne</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cochin Hospital</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Antoine Hospital</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Paris Saint Joseph</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75674</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <state>Ile et Vilaine</state>
        <zip>35203</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Tours</name>
      <address>
        <city>Tours</city>
        <state>Indre-et-Loire</state>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Grenoble</name>
      <address>
        <city>Grenoble</city>
        <state>Isère</state>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Nantes</name>
      <address>
        <city>Nantes</city>
        <state>Loire-Atlantique</state>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Reims</name>
      <address>
        <city>Reims</city>
        <state>Marne</state>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Fort de France</name>
      <address>
        <city>Fort de France</city>
        <state>Martinique</state>
        <zip>97 261</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Lille</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Rouen</name>
      <address>
        <city>Rouen</city>
        <state>Seine-Maritime</state>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Amiens</name>
      <address>
        <city>Amiens</city>
        <state>Somme</state>
        <zip>80000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Louis Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2011</study_first_submitted>
  <study_first_submitted_qc>February 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2011</study_first_posted>
  <last_update_submitted>January 31, 2014</last_update_submitted>
  <last_update_submitted_qc>January 31, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>scleroderma</keyword>
  <keyword>digital</keyword>
  <keyword>ulcer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Scleroderma, Localized</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

